Three biotechs hunt $336M-plus in a new round of IPOs — while Der­ma­vant pulls back

Raise mon­ey when you can, not when you must — the com­mon re­frain rang loud in two IPO fil­ings late Fri­day as ADC Ther­a­peu­tics and Fre­quen­cy Ther­a­peu­tics looked to top up their re­cent rais­es with mega IPOs.

But when you can’t, as Der­ma­vant found af­ter a sec­ond try, then quit­ting might be im­per­a­tive.

ADC and Fre­quen­cy were joined by lit­tle can­cer biotech Aprea Ther­a­peu­tics, seek­ing a col­lec­tive $336 mil­lion from Wall Street.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.